Xenetic Biosciences, Inc. (XBIO) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Xenetic Biosciences, Inc. is a biopharmaceutical company focused on immune-oncology technologies, specifically its proprietary Deoxyribonuclease (DNase) program targeting neutrophil extracellular traps (NETs) for pancreatic carcinoma and solid tumors. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $806,923 | $593,261 |
| Net Loss | $(456,382) | $(903,141) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.59) |
| Cash and Cash Equivalents | $7,347,255 | $5,163,676 |
| Working Capital | $6,636,831 | $N/A (Derived) |
| Total Liabilities | $958,239 | $N/A |
| Accumulated Deficit | $(200,331,713) | $(198,097,612) |
Operating Expenses: Total operating costs were $1,309,040, comprising $661,443 in Research and Development (R&D) and $647,597 in General and Administrative (G&A) expenses. Interest income was $45,756.
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenue increased by 36.0% ($213,662) compared to Q1 2025, driven by royalties from the Takeda sublicense agreement.
- Expense Reduction: R&D expenses decreased by 24.8% ($217,586) due to lower pre-clinical study costs, partially offset by increased manufacturing development. G&A expenses decreased slightly by 1.4%.
- Improved Profitability: Net loss improved significantly, decreasing by 49.5% year-over-year to $(456,382).
- Liquidity: Cash balances increased by approximately $2.2 million compared to the prior year period, though cash decreased by $536,377 during the current quarter due to operating cash outflows.
Guidance, Outlook, and Strategic Developments
Strategic Review: The Board has initiated a formal strategic review process with outside advisors to maximize shareholder value. Alternatives under consideration include the sale of all or part of the company, asset sales, or a business combination (including a "reverse merger"). No definitive agreement has been reached, and there is no assurance a transaction will occur.
Going Concern: Management believes existing resources, bolstered by a $4.0 million equity offering in October 2025, are sufficient to fund operations for at least twelve months. However, the company anticipates needing additional capital in the long term.
Risks: Key risks include the uncertainty of the strategic review outcome, the need for future financing, and the impact of geopolitical events (Ukraine, Middle East) on operations. The company has no material legal proceedings pending.
Investor Verification Checklist
- Strategic Review Status: Monitor for updates on the potential sale or merger discussions, as this could fundamentally alter the company's structure or stock ownership.
- Cash Burn Rate: Verify the sustainability of the $7.3 million cash balance against the ~$0.5 million quarterly operating cash burn.
- Royalty Dependency: Assess the stability of revenue, which is currently derived entirely from Takeda royalties, as the company has no commercial products of its own.
- Capital Needs: Review future financing plans given the accumulated deficit of over $200 million and the lack of product revenue.
- Related Party Transactions: Note ongoing agreements with related parties (e.g., PeriNess, Dr. Dmitry Genkin) and their financial impact.